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Summary
Objective: Disruption of the vascular supply to the bone and subsequent hypoxia has been implicated in the pathogenesis of osteonecrosis of
the femoral head (ONFH). Vascular endothelial growth factor (VEGF ), a major inducer of angiogenesis, has been correlated with several patho-
logical conditions, from inﬂammation to ischemic processes. A number of polymorphisms in the VEGF gene have been described as being
associated with several diseases, such as diabetic retinopathy, prostate cancer and breast cancer. The aim of this study was to evaluate
the association of VEGF gene polymorphisms with ONFH in a caseecontrol study.
Methods: Three polymorphisms (2578C>A, 634G>C and þ936C>T) in VEGF were genotyped in 317 ONFH patients and 497 control
subjects, using the TaqMan 50 allelic discrimination assay. We performed the association analysis of genotyped single nucleotide polymor-
phisms (SNPs) and haplotypes with ONFH.
Results: The 634G>C genotype was signiﬁcantly associated with an increased risk for ONFH in dominant model with odds ratio (OR) of
1.47, 95% conﬁdence intervals (CIs) 1.08e2.01 with P value 0.015. Further analysis stratiﬁed by sex showed that the 634G>C genotype
was also signiﬁcantly associated with a high risk for male patients considering the dominant model with OR of 1.60, 95% CI 1.13e2.26
with P value 0.008. Haplotype association analysis did not provide a further delineation of the risk allele.
Conclusion: Our study is, to our knowledge, the ﬁrst report that shows the 634G>C polymorphism in the VEGF promoter was associated
with an increased susceptibility of ONFH in the Korean population.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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287interruption in the vascular supply of blood or a decreased
blood ﬂow. While ON can occur in many anatomical loca-
tions, the femoral head is most commonly affected. This
is probably because of restricted perfusion1,2. As ON of
the femoral head (ONFH) is a devastating disease that fre-
quently leads to the progressive collapse of the femoral
head, followed by degenerative arthritis of the hip joint, it
mainly affects middle-aged men resulting in both a reduction
in the quality of life and a tremendous amount of pain. The
disease incurs substantial socioeconomic costs, as well as
a burden for patients and their families3,4.
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has been suggested that a common pathogenesis of ONFH
involves an interruption of the circulation of blood to anteriore
superiorelateral part of the femoral head, thus leading to
ischemic insult and bone collapse5. The disease can be
aggravated by several factors including steroid administra-
tion6, alcohol abuse7, arterial thrombosis or hypoﬁbrinolysis8,
and systemic lupus erythematosus9.
Angiogenesis is an important part of the bone repair pro-
cess, and the close connection between blood vessels and
bone has already been recognized10. Recently, the vascu-
lar endothelial growth factor (VEGF ) gene transfer, using
the adenoviral vector in a rabbit model of ON, resulted in
the enhanced neovascularization of the necrotic bone11,12.
Signiﬁcantly, VEGF is highly expressed in the edematous
area of the ON adjacent to the necrotic area13, indicating
that VEGF expression is correlated with bone tissue re-
pair14. VEGF is important for bone formation, such as nor-
mal growth plate morphogenesis, which includes blood
vessel invasion and cartilage remodeling15. VEGF has
also been implicated in bone repair16.
VEGF, a major inducer of angiogenesis during embryo-
genesis, has been implicated in neuronal survival, neuro-
protection, regeneration, growth, differentiation, and
migration17e19. It has also been correlated with several
pathological conditions, from tumor proliferation to inﬂam-
matory and ischemic processes. The VEGF gene was re-
ported to be polymorphic, especially in the promoter region
(2578, 1154, etc.), the 50-untranslated region (UTR)
(634, 7) and in the 30-UTR (þ936). Several studies
have shown that polymorphisms within the 50-UTR have
lead to differences in VEGF expression, and that they could
inﬂuence the etiology of a variety of pathological conditions
such as diabetic retinopathy20,21, prostate cancer22,23, and
breast cancer24.
Although there are various studies on the role of VEGF
regarding bone repair for osteonecrotic bone15,16, none of
them have investigated the effects of the genetic polymor-
phisms of VEGF on ONFH. In previous study of VEGF with
other diseases in Korea, VEGF gene was fully sequenced
and linkage disequilibrium (LD) was estimated25. It has
also been reported that the polymorphisms of VEGF pro-
moter were associated with many diseases in Korea25,26.
Therefore, in the present study, we have focused on the
50-UTR, a promoter region, and the 30-UTR of VEGF for ge-
netic analysis of ONFH, as they have been shown to be
highly polymorphic and reported to be associated with
many diseases. We investigated the relationship between
the incident risk for ONFH and polymorphisms in the genes
for VEGF, which may be the major signal to couple angio-
genesis and osteogenesis during bone repair.Materials and methodsSUBJECTSBlood samples and records were obtained from 317 unrelated patients
with ONFH (255 men, 62 women; age: 49.7 14) and 497 control subjects
(396 men, 101 women; age: 41.6 15) who visited Kyungpook National Uni-
versity Hospital (Daegu, Korea) for medical check up between 2002 and
2005. Diagnoses were established by the evidence of ON on magnetic res-
onance imaging (MRI) in Stage 1 of association research circulation osseons
(ARCO)27 classiﬁcation system and plain radiographs in Stages 2, 3 and 4.
The diagnosis of symptomatic ON was made using anteroposterior and lat-
eral-pelvic radiographs and MRIs. Patients with a demonstrable history of di-
rect trauma or with the possibility of a combination of causes were excluded.
Control subjects were recruited from spouses of the patients and the general
population. All individuals provided informed consent for their participation in
the study and this project was approved by the Institutional Review Board.GENOTYPING WITH FLUORESCENCE POLARIZATION
DETECTIONFor the genotyping of polymorphic sites, amplifying primers and probes
were designed for the TaqMan assay30. Primer Express (Applied Biosystems)
was used to design both the polymerase chain reaction (PCR) primers and
the MGB TaqMan probes. One allelic probe was labeled with the 6-carboxy-
ﬂuorescein (FAM) dye and the other was labeled with the ﬂuorescent VIC
dye. PCRs were run in the TaqMan Universal Master mix without UNG (Ap-
plied Biosystems), with PCR primer concentrations of 900 nM and TaqMan
MGB-probe concentrations of 200 nM. Reactions were performed in a 96-
well plate format in a total reaction volume of 10 ml using 20 ng of genomic
DNA. The plates then were placed in a thermal cycler (7500HT, Applied Bio-
systems) and heated at 50C for 2 min and 95C for 10 min, followed by 40
cycles at 95C for 15 s and at 60C for 1 min. The ﬂuorescence intensity in
each well of the plate was read. Fluorescence data ﬁles from each plate
were analyzed using automated allele-calling software (SDS 2.1, Applied Bi-
osystems). Genotyping quality control was performed in 10% of the samples
by duplicate checking.STATISTICSWe used c2 tests to determine whether individual variants were in Har-
dyeWeinberg equilibriumat each locus in the population. Logistical regression
analyses were used to calculate the odds ratios (ORs) and their 95% conﬁ-
dence intervals (CIs) for SNP sites. The P values of the codominant, dominant
and recessive models are shown. The haplotypes of each individual and their
frequencies were constructed with an EM algorithm31 and a permutation test
was performed with genotyped SNPs. A Fisher’s exact test or c2 test was
applied in order to compare the frequency of discrete variables between the
controls and patients. A P value of less than 0.05 was considered to be statis-
tically signiﬁcant.Results
In order to investigate the association of VEGF gene
polymorphism with ONFH, we analyzed the genotype of
three SNPs (2578C>A, 634G>C and þ936C>T), one
(2578C>A) in promoter region, one (634G>C) in the
50-UTR and one (þ936C>T) in the 30-UTR, by a TaqMan
assay. The genotype frequencies between ONFH patients
and control groups were compared.
The genotype distributions of all loci were within the
HardyeWeinberg equilibrium (P> 0.05) (Table I). The P
values of each polymorphism were analyzed with respect to
a comparison between ONFH patients and the controls
(Table II). The genotype and allele frequencies of634G>C,
in ONFH patients, were signiﬁcantly different from those in
the control group with P values 0.050, 0.037 (OR; 1.24,
95% CI; 1.01e1.52), respectively. In dominant genetic anal-
ysis, carriers of C allele in634G>C (GCþCC) were signif-
icantly higher in the ONFH patients than in the controls
(73.4% vs 65.3%, P¼ 0.015, OR; 1.47, 95% CI;
1.08e2.01). Next, since we observed a tendency showing
a high incidence of ONFH in men and that the majority of pa-
tients in this study were male, the association of VEGF poly-
morphisms was further analyzed with ONFH subgroups
stratiﬁed by sex. When compared to controls, the minor
allele (C) of 634G>C showed a signiﬁcantly higher
frequency in ONFH patients than in controls (P¼ 0.040,
OR; 1.27, 95% CI; 1.01e1.59) in male subgroup. The
634G>C genotype was also signiﬁcantly associated with
an increased risk for ONFH in codominant and dominant
models (P¼ 0.028, OR; 1.31 (1.04e1.64) and P¼ 0.008,
OR; 1.60 (1.13e2.26), respectively), suggesting that theCal-
lele of 634G>C contributed to the susceptibility of ONFH.
Theallele frequency of theCallele of634G>C in female pa-
tients was similar to the males, but the association between
female patients and control was statistically not signiﬁcant.
This result is probably due to their small number of female pa-
tients (control 101, case 62) in our study (Table III), and
a larger sample size may be required.
Table I
Frequencies of VEGF polymorphisms in ONFH subjects
Loci Position rs# Genotype Frequency Heterozygosity HWE*
Controls Patients
2578C>A Promoter rs699947 C CA A N 0.266 (A) 0.390 0.744 0.266
429 328 51 808
634G>C 50-UTR rs2010963 G GC C N 0.428 (C) 0.490 0.776 0.087
255 414 138 807
þ936C>T 30-UTR rs3025039 C CT T N 0.194 (T) 0.313 0.903 0.977
519 254 29 802
*P values of deviation from HWE among ONFH patients and normal subjects.
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phisms, which indicated that 2578 and 634 polymor-
phisms are in tight LD, and that þ936 polymorphism was
only weakly associated with the other polymorphisms
(Table IV). Based upon the LD coefﬁcients, haplotypes
were reconstructed and compared haplotype frequencies
between normal controls and ONFH patients.
As shown in Table V, the frequency CC haplotype was
signiﬁcantly higher in patients with ONFH, conferring a
risk for disease (P¼ 0.032, OR; 1.25, 95% CI; 1.02e1.53).
Haploype, CG, was signiﬁcantly lower in patients, suggest-
ing that CG haplotype bearing 634G allele had protective
effect against ONFH (P¼ 0.047, OR; 0.80, 95% CI;
0.64e1.00). However, since haplotype association analysis
did not provide a higher OR or a more signiﬁcant result, the
effect may be brought about by the SNP-634G>C itself or by
a mutation in complete LD with this SNP.
These results suggest that the 634G>C polymorphism
of the VEGF promoter might be associated with an in-
creased susceptibility of ONFH in the Korean population.
In addition, this polymorphism may contribute to future stud-
ies regarding VEGF functions and ON.Table I
Genotypes and allelic frequencies of the VEGF gene po
Position* Genotype Control, n (%)
2578C>A CC 263 (53.0)
CA 199 (40.1)
AA 34 (6.85)
CAþAAz 233 (47.0)
C 725 (73.1)
A 267 (26.9)
634G>C GG 172 (34.8)
GC 243 (49.1)
CC 80 (16.2)
GCþCCz 323 (65.3)
G 587 (59.3)
C 403 (40.7)
þ936C>T CC 317 (64.4)
CT 157 (31.9)
TT 18 (3.66)
CTþ TTz 175 (35.6)
C 791 (80.4)
T 193 (19.6)
*Calculated from the translation start site.
yLogistic regression analyses were used for calculating OR (95% CI).
zDominant analysis: homozygotes for the major allele vs heterozygoteDiscussion
Although many pathophysiological models of bone necro-
sis have been proposed, the precise mechanism of ONFH
has not been completely elucidated. Among several con-
founding pathogenic mechanisms for ONFH, a vascular hy-
pothesis appears to be the most persuasive, presuming that
a decrease in the local blood ﬂow in the femoral head, due
to vascular obstruction by any means, plays a pivotal role in
the pathogenesis of ONFH32,33. All factors that decrease
blood ﬂow and lead to vascular insufﬁciency contribute to
ON. Several studies, in human and animal models of
ONFH, have shown that vascular abnormalities have re-
sulted in thrombosis associated with abnormal thrombo-
philic coagulopathy and hypoﬁbrinolysis and embolism,
which contribute to the development of ONFH8,34,35. A re-
duction in shear stress, due to decreased blood ﬂow, could
also lead to the apoptosis of endothelial cells, which can ul-
timately contribute to osteogenesis as releasing osteogenic
factors. The dysregulation of endothelial cell activating fac-
tors and stimulators of angiogenesis or repair processes
could also affect the progression and outcome of
ONFH33. A diminished blood ﬂow, resulting from capillaryI
lymorphisms between ONFH patients and controls
ONFH, n (%) ORy (95% CI) P
166 (53.2) 1.00 0.647
129 (41.3) 1.03 (0.76e1.38)
17 (5.45) 0.79 (0.43e1.46)
146 (46.8) 0.99 (0.75e1.32) 0.960
461 (73.9) 1.00 0.725
163 (26.1) 0.96 (0.77e1.21)
83 (26.6) 1.00 0.050
171 (54.8) 1.46 (1.05e2.02)
58 (18.6) 1.50 (0.98e2.30)
229 (73.4) 1.47 (1.08e2.01) 0.015
337 (54.0) 1 0.037
287 (46.0) 1.24 (1.01e1.52)
202 (65.2) 1.00 0.990
97 (31.3) 0.98 (0.72e1.33)
11 (3.55) 1.00 (0.46e2.16)
108 (34.8) 0.97 (0.72e1.30) 0.833
501 (80.8) 1 0.836
119 (19.2) 0.97 (0.75e1.26)
sþ homozygotes for the minor allele.
Table III
Association of genotypes and alleles between the ONFH patients and controls stratified by sex
Subgroups Loci Normal
controls
ONFH
patients
Codominant Dominant Allele
OR*(95% CI) Py OR (95% CI) P OR (95% CI) P
n¼ 396 n¼ 255
Male 2578C>A 0.262 0.262 1.02 (0.79e1.32) 0.629 1.06 (0.77e1.46) 0.713 1.00 (0.78e1.29) 0.999
634G>C 0.402 0.460 1.31 (1.04e1.64) 0.028 1.60 (1.13e2.26) 0.008 1.27 (1.01e1.59) 0.040
þ936C>T 0.205 0.184 0.90 (0.68e1.20) 0.601 0.84 (0.60e1.18) 0.316 0.88 (0.66e1.17) 0.365
n¼ 101 n¼ 62
Female 2578C>A 0.297 0.258 0.80 (0.47e1.37) 0.705 0.76 (0.41e1.44) 0.407 0.82 (0.50e1.36) 0.448
634G>C 0.426 0.459 1.19 (0.73e1.93) 0.613 1.04 (0.51e2.11) 0.908 1.14 (0.73e1.80) 0.559
þ936C>T 0.163 0.225 1.54 (0.86e2.75) 0.291 1.69 (0.87e3.30) 0.122 1.49 (0.84e2.62) 0.170
*Logistic regression analyses were used for calculating OR (95% CI).
yValues were analyzed by c2 test.
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intraosseous pressure and secondary arterial ischemia. Is-
chemia-induced necrosis can result in a collapse of the joint
cartilage and subchondral bone36,37. During hypoxia, hyp-
oxia-inducible factors bind to the hypoxia-responsive ele-
ments and the expression of VEGF can be induced. This
leads to the stimulation of angiogenesis38e40.
VEGF, a major inducer of angiogenesis, is important for
bone formation processes, such as normal growth plate
morphogenesis, including blood vessel invasion and carti-
lage remodeling15 and it has also been implicated in bone
repair16,33. These reports indicate that normal angiogenesis
is central to tissue repair, and that VEGF may be the major
signal in the coupling of angiogenesis and osteogenesis
during bone repair14,41.
The VEGF gene was reported to be polymorphic, espe-
cially in the promoter region, the 50-UTR and in the 30-UTR.
Several transcription factor binding sites are found in the
VEGF 50-UTR and the transcriptional regulation of the
gene is extremely complex42. Several studies have shown
that polymorphisms within the 50-UTR have lead to differ-
ences in VEGF expression between individuals and that
they could inﬂuence the etiology of a variety of pathological
conditions such as diabetic retinopathy20 and Type 1 diabe-
tes mellitus43, with which VEGF has been associated.
In this study, we examined the potential association of
VEGF polymorphisms with ONFH in Korean patients. First,
we identiﬁed a signiﬁcant association between the
634G>C polymorphism and the risk of ONFH. We also
analyzed the 2578C>A and þ936C>T polymorphisms
of VEGF, but neither was associated with the risk of
ONFH. Haplotype analysis also suggested the importance
of 634G>C in susceptibility to ONFH. However, haplotype
analysis did not provide a further delineation of the risk al-
lele (as indicted by the similar effect sizes, P values and
the fact that the haplotype bears the C allele alone),Table IV
Allele frequency and pairwise LD estimates among SNPs in VEGF
gene
SNPs jD’j
2578C>A 634G>C
(50-UTR)
þ936C>T
(30-UTR)
r2 2578C>A e 1 0.238
634G>C (50-UTR) 0.271 e 0.008
þ936C>T (30-UTR) 0.038 0 e
Minor allele (freq. %) A (26.6) C (42.8) T (19.4)indicating that the effect may be driven by the 634G>C
SNP itself or by a mutation in complete LD with this SNP.
Although many etiological factors contributed to patho-
genesis of ONFH, the pathologic changes of bone marrow
in ONFH were almost similar2 and it is commonly accepted
that the ﬁnal common pathway for the development of
ONFH involves an interruption of the circulation of blood. Al-
though the allele frequency of the C allele of 634G>C in
female patients was similar to the males, we were not
able to detect an association between 634G>C polymor-
phisms and female patients of ONFH. Our present study
has some limitations. The incidence of ONFH is relatively
low and sex-biased. The number of cases in only 317, of
which the mayority (80%) are males. And also, epidemio-
logic study has shown that alcohol-induced ONFH is most
prevalent in Korea. The frequency of idiopathic and ste-
roid-induced ON is relatively low. Therefore, association
analysis strategy with subgrouped by sex or etiology also
has some limitations such as sample number and sex-bi-
ased sample. In this study, female patients may not be large
enough to assess a powerful stratiﬁed association analysis
(control 101, case 62). Hence, the association might be
false negative due to the small sample size and not statis-
tically relevant (Table III). Nevertheless, it might be worth-
while to follow up the importance of the VEGF
polymorphism with other subgroups (etiology, sex) of
ONFH through larger cohort studies, considering its associ-
ation with the risks of ONFH.
According to Watson et al.44, the 634G>C polymor-
phism was signiﬁcantly correlated with the VEGF expres-
sion of lipopolysaccharide (LPS)-stimulated peripheral
blood mononuclear cells (PBMC). The VEGF production
was the highest for the GG homozygotes and the lowest
for the CC homozygotes, and it also suggested that LPS
may work through the myeloid zinc ﬁnger protein (MZF1)
binding site, within which the 634G>C polymorphismTable V
Estimated haplotype frequencies of selected SNPs in ONFH
patients and controls
Haplotype* Overall
2578C>A 634G>C Control Case OR (95% CI) Py
C C 0.407 0.461 1.25 (1.02e1.53) 0.032
C G 0.324 0.277 0.80 (0.64e1.00) 0.047
A G 0.269 0.261 0.96 (0.77e1.21) 0.744
*Values were constructed by EM algorithm with genotyped
SNPs.
yValues were analyzed by permutation test.
291Osteoarthritis and Cartilage Vol. 16, No. 3was predicted to be located. Therefore, we have suggested
that decreased VEGF expression in the osteonecrotic bone
area could affect angiogenesis, repair processes, the pro-
gression, and outcome of ONFH. Since the VEGF gene is
highly polymorphic, there is the possibility that if the impact
of a single locus is not overwhelming, the net effect of mul-
tiple polymorphisms may determine a VEGF production,
thus conferring the clinical manifestations.
These results suggest that 634G>C polymorphism of
the VEGF promoter is likely to be associated with suscepti-
bility to ONFH. To our knowledge, our study is the ﬁrst re-
port that shows the VEGF polymorphisms and haplotypes
are associated with ONFH in Korea. Further biological
and/or functional evidences would be needed to conﬁrm
the suggestive correlations between the VEGF polymor-
phism and ONFH.
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